Skip to end of metadata
Go to start of metadata

You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 20 Next »


This shared data set was provided by the Breast Imaging Research Program at UCSF, in collaboration with ACRIN (American College of Radiology Imaging Network), the I-SPY TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and molecular Analysis), and TCIA.

Funding sources include:

UCSFR01 CA132870 and U01 CA151235
ACRINCA079778 and CA080098
I-SPYCA31964 and CA33601

David Newitt, PhD, UCSF
Nola Hylton, PhD, UCSF  



ACRIN 6657 was designed as a prospective study to test MRI for ability to predict response to treatment and risk-of-recurrence in patients with stage 2 or 3 breast cancer receiving neoadjuvant chemotherapy (NACT). ACRIN 6657 was conducted as a companion study to CALGB 150007, a correlative science study evaluating tissue-based biomarkers in the setting of neoadjuvant treatment of breast cancer. Collectively, CALGB 150007 and ACRIN 6657 formed the basis of the multicenter Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis (I-SPY TRIAL) breast cancer trial, a study of imaging and tissue-based biomarkers for predicting response and survivalAdd protocol references for all three studies.
Participant Eligibility and Enrollment: Criteria for inclusion were patients enrolling on CALGB 150007 with T3 tumors measuring at least 3 cm in diameter by clinical exam or imaging and receiving neoadjuvant chemotherapy with an  anthracycline-cyclophosphamide regimen alone or followed by a taxane. Pregnant patients and those with ferromagnetic prostheses were excluded from the study. The study was open to enrollment from May 2002 to March 2006. 237 patients were enrolled, of which 230 met eligibility criteria.

Requirements for MR imaging (As specified in the ACRIN 6657 protocol )

Imaging time points: MRI exams were performed within four weeks prior to starting anthracycline-cyclophosphamide chemotherapy (T1, MRI1), at least 2 weeks after the first cycle of AC and prior to the second cycle of AC (T2, MRI2), between anthracycline-cyclophosphamide treatment and taxane therapy if taxane was administered (T3, MRI3), and after the final chemotherapy treatment and prior to surgery (T4, MRI4). The study schema is shown in Figure 1

Figure 1. I-SPY 1 TRIAL and ACRIN 6657 study schema.

Imaging protocol: MR imaging was performed on a 1.5 Tesla field strength scanner using a dedicated breast radiofrequency coil. The image acquisition protocol included a localization scan and T2-weighted sequence followed by a contrast-enhanced T1-weighted series. All imaging was performed unilaterally over the symptomatic breast and in the sagittal orientation. The contrast-enhanced series consisted of a high resolution (≤1mm in-plane spatial resolution) three-dimensional, fat-suppressed, T1-weighted gradient echo sequence with TR≤20 ms, TE = 4.5 ms, flip angle ≤ 45º, 16-18 cm field-of-view, minimum matrix 256x192, 64 slices, slice thickness ≤ 2.5 mm. Scan time length for the T1-weighted sequence was required to be between 4.5 and 5 minutes. The sequence was acquired once before contrast injection and repeated at least twice following injection.
Tumor diameter measurement and volumetric analysis: Tumor longest diameter (LD) was measured by the site radiologist as the greatest extent of disease on baseline MR images, including intervening areas of non-enhancing tissue. The same measurement direction was used on all subsequent MRI exams. The primary predictor variable, functional tumor volume (FTV) was measured from contrast-enhanced images using the signal enhancement ratio (SER) method. Voluetric analysis, including Quality Control assessment, was performed centrally at the breast MR imaging laboratory at University of California at San Francisco (UCSF).

Further information can be found at:


ACRIN  American College of Radiology Imaging Network
I-SPY TRIAL  Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis
CALGB  Cancer and Leukemia Group B
NACT  Neoadjuvant chemotherapy
FTV  Functional Tumor Volume

Data Access

Imaging Data

This is a limited access data set. To request access, please contact (ACRIN Contact). If access is granted you will be able to view and download these images on The Cancer Imaging Archive (TCIA) by logging in and selecting the I-SPY1 collection. This data set will be made publicly available on or before XXXX XX, 20XX.

Collection Statistics

(updated 6/18/2015)



Number of Patients


Number of Studies


Number of Series


Number of Images


Images Size (GB)76.2 GigaBytes

((( Insert full acknowledgement lists here )))


ISPY 1 - Collection Description

If you are unsure how to download this Collection please view our quick guide on Searching by Collection or refer to our The Cancer Imaging Archive User's Guide for more detailed instructions on using the site.

Imaging Data Transfer Process

The processing of the MR image data for ACRIN 6657 / I-SPY 1 consisted of the following steps between image acquisition and the creation of this shared data set on TCIA:

  • MRI studies were sent from the study centers to ACRIN Core Lab either via media (DVD) or the TRIAD program
  • Image data were de-identified and centrally archived at ACRIN Core Lab
  • Archived data was sent to the breast MR imaging laboratory at University of California at San Francisco (UCSF) for volumetric analysis.
  • De-identified image data, derived analysis maps and segmentations, and ancillary data files were transferred from UCSF to TCIA for data sharing.

While every effort was made to preserve the integrity of both the original image data and image meta-data (DICOM attributes, public and private), strict adherence to HIPPA guidelines for patient confidentiality may have resulted in loss of some data. If any questions arise, or any patient PHI is found in any data on this collection, please contact David Newitt at the Breast Imaging Research Program, UCSF ( 

In addition to the complete set of ACRIN 6657 imaging studies, curated data sets based on UCSF QC assessment and data completeness are provided in the form of TCIA shared lists for selective downloads. 

Shared Lists: See descriptions below under "Curated Data Sets"

Level 0: All I-SPY 1 Dataset

847 MR on-study studies (222 subjects) in UCSF image database.
One patient in the image data collection (I-SPY ID 1079 ) does not appear in the Feb. 2, 2011 I-SPY FINAL LOCKED clinical data set. So no clinical data is available.

Level 1: LD Dataset

Studies with MRI measured longest diameter
839 MR studies have LD reported in the I-SPY 1 clinical database
834 MR studies (219 subjects) in UCSF image database with LD

5 studies that have LD measurement are missing from
the UCSF and ACRIN TRIAD image data collections:

1071, T1
1138, T1

1101, T3
1040, T4

1187, T4

Level 2a: Good SER Volume Dataset – updated 9/3/14

708 MR studies (208 subjects) in UCSF image database

7 studies in Level 2a that do NOT have LD measures:

ID 1059, T4
ID 1079, T2 *
ID 1104, T4

ID 1192, T2
ID 1212, T4

ID 1215, T1
ID 1238, T2

  • Patient 1079 does not appear in the Feb. 2, 2011 I-SPY FINAL LOCKED clinical data set. So no clinical data is available.

Level 2b: SER Volume Dataset submitted to ACRIN in 2008

707 MR studies (207 subjects) in UCSF image database
Differences between Levels 2a and 2b:

15 exams accepted for SER analysis since 2008 (in Level 2a but not in 2b)

ID 1005, T3
ID 1043, T2
ID 1046, T4
ID 1057, T3
ID 1074, T3
ID 1084, T1

ID 1110, T4
ID 1139, T4
ID 1159, T4
ID 1176, T2
ID 1201, T2

ID 1203, T4
ID 1206, T4
ID 1225, T3
ID 1219, T3
ID 1228, T4

14 exams rejected since 2008 (in Level 2b but not in 2a)

ID 1035, T4
ID 1045, T1
ID 1047, T1
ID 1053, T2
ID 1053, T4

ID 1055, T1
ID 1086, T1
ID 1091, T1
ID 1095, T2
ID 1173, T3

ID 1206, T1
ID 1206, T2
+2 exams for ineligible patient:
ACRIN ID 128 (no I-SPY ID)

Data Dictionary

A data dictionary is provided. The dictionary includes descriptions of all private DICOM attributes used in the derived maps and segmentations generated by the volumetric analysis and QC evaluations. Also included are descriptions of ancillary data provided, including demographic, clinical and survival data.

  • No labels